NASDAQ
According to Zyberno, NUTEX HEALTH INC. (NUTX) is a buy opportunity — GREAT BUSINESS (83/100) trading at a Margin of Safety of +84.5% against historical owner earnings, with a Brina Gap of +11.6% confirming the market is underestimating its forward growth capacity.
According to Zyberno's DCF model, NUTEX HEALTH INC. (NUTX) trades at $189.25 against an estimated intrinsic value per share of $1,218.35 — a +84.5% Margin of Safety based on Owner Earnings of $269.02M TTM, projected at 100.0% growth for 10 years with a 2.5% terminal growth rate. The Brina Gap of +11.6% strengthens the case: based on the company's ROIC (87.7%) and reinvestment rate (-6.0%), the business can fundamentally grow at -5.3% — but the current enterprise value implies the market expects -16.8%. This places NUTX in the Double Discount quadrant of the Brina Matrix, the rarest and most attractive position. Zyberno's model translates this into a 5-year expected return of 74.2% annually.
Over the trailing twelve months, NUTX generated $269.02M in Owner Earnings. Capital was deployed as follows: $31.73M returned via share buybacks, $3.66M invested in capital expenditures. Reinvestment rate: -6.0%. Owner Earnings have grown at 100.0% annually over the trailing five years using log-linear regression.